Clinical trial
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone…
NCT00452387 · Accelerated Community Oncology Research Network, Other · Terminated
Key facts
| NCT number | NCT00452387 |
|---|---|
| Title | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) |
| Official title | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Accelerated Community Oncology Research Network, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Mitoxantrone, Prednisone, Sorafenib |
| Enrollment | 22 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Mar 27, 2007 |
| Last update posted | Sep 16, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: